Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine
E. Kondratyeva (Moscow, Russian Federation), V. Shadrina (Perm, Russian Federation), E. Furman (Perm, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), E. Zhekaite (Moscow, Russian Federation), O. Simanova (Moscow, Russian Federation), A. Malakhov (Moscow, Russian Federation), M. Mukhina (Moscow, Russian Federation), E. Yakushina (Moscow, Russian Federation), O. Vysokolova (Moscow, Russian Federation), . Ilyenkova (Krasnoyarsk, Russian Federation), S. Trishina (Simferopol, Russian Federation), J. Pinegina (Novosibirsk , Russian Federation), T. Safonova (Omsk, Russian Federation), E. Vasilyeva (Samara, Russian Federation), O. Golubtsova (Cheboksary, Russian Federation)
Source: Virtual Congress 2021 – Cystic fibrosis
Session: Cystic fibrosis
Session type: E-poster
Number: 2196
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Kondratyeva (Moscow, Russian Federation), V. Shadrina (Perm, Russian Federation), E. Furman (Perm, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), E. Zhekaite (Moscow, Russian Federation), O. Simanova (Moscow, Russian Federation), A. Malakhov (Moscow, Russian Federation), M. Mukhina (Moscow, Russian Federation), E. Yakushina (Moscow, Russian Federation), O. Vysokolova (Moscow, Russian Federation), . Ilyenkova (Krasnoyarsk, Russian Federation), S. Trishina (Simferopol, Russian Federation), J. Pinegina (Novosibirsk , Russian Federation), T. Safonova (Omsk, Russian Federation), E. Vasilyeva (Samara, Russian Federation), O. Golubtsova (Cheboksary, Russian Federation). Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine. 2196
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Efficacy and safety of omalizumab in real-life practice in India Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012
The efficacy and safety of new combined medicinal product in the treatment of influenza: The results of a multicenter randomized comparative clinical trial Source: Annual Congress 2013 –Viral infections: what is new? Year: 2013
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study Source: ERJ Open Res, 4 (4) 00084-2018; 10.1183/23120541.00084-2018 Year: 2018
Evaluation of data requirements to establish biologic quality control ranges in a multi-center clinical trial for inhaled insulin Source: Annual Congress 2008 - New challenges and maintained quality: lung function for the future Year: 2008
Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019
Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021
Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019
Clinical effectiveness of self-management of asthma in general practice: a randomized controlled trial Source: Eur Respir J 2001; 18: Suppl. 33, 518s Year: 2001
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability Source: Eur Respir J, 51 (2) 1701531; 10.1183/13993003.01531-2017 Year: 2018
An observational study assessing the practice of long-term azithromycin prescription in bronchiectasis Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 78s Year: 2002
Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019
Evaluation of biological quality control variance in a multi-center clinical trial for inhaled insulin Source: Annual Congress 2007 - Quality, sleep and physiology Year: 2007
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018